Dr. Bianchi on Diagnostic Factors for AL Amyloidosis

Video

In Partnership With:

Giada Bianchi, MD, discusses diagnostic factors for light chain amyloidosis.

Giada Bianchi, MD, a physician at Dana-Farber Cancer Institute, and an instructor in medicine at Harvard Medical School, discusses diagnostic factors for light chain (AL) amyloidosis.

Diagnostic delay remains as a notable challenge in AL amyloidosis, according to Bianchi. Patients who have advanced cardiac involvement often express disease symptoms for months and possibly years, Bianchi explains. Notably, this disease is a mimicker and can present with subtle symptoms at the outset, which can make the diagnostic process challenging, she says.

Depending on the organ that is involved, patients can present with a variety of symptoms. ​​​​​​​As such, it is important to be aware that any patient who has progressive symptoms of unclear nature, particularly those with smoldering myeloma, should be screened for AL amyloidosis, Bianchi concludes.

Related Videos
Saad Z. Usmani, MD, MBA, FACP, FASCO
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center
Francesco Di Meo, PhD
Hans Lee, MD, associate professor, director, Multiple Myeloma Clinical Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Haeseong Park, MD, MPH
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Jennifer Brown, MD, PhD
Rebecca L. Porter, MD, PhD